


**Amendments to the claims**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**What is claimed is:**

**Claims**

1. (Original) A compound of formula (I),



or a pharmaceutically acceptable salt or solvate thereof, wherein,

P represents phenyl, quinolinyl, isoquinolinyl, 1,2,3,4-tetrahydroquinolinyl, benzoisoxazolyl or benzothiazolyl;

P' represents phenyl, pyridinyl, pyrimidinyl, pyridazinyl or benzothiazolyl;

R<sup>1</sup> and R<sup>2</sup> may be the same or different and represent alkyl, alkoxy, halo, -CF<sub>3</sub>, -OCF<sub>3</sub>, -OH, =O, -CN, -NO<sub>2</sub>, -SO<sub>2</sub>NH<sub>2</sub>, -SO<sub>2</sub>R<sup>3</sup> or -NR<sup>3</sup>R<sup>4</sup>;

R<sup>3</sup> and R<sup>4</sup> may be the same or different and represent -H or alkyl;

m represents 0 or 1;

n represents 0, 1, 2, 3, 4 or 5; and

X represents N or CH;

with the proviso that said compound of formula (I) is not a compound selected from:

4-Phenyl-N-quinolin-7-yl-piperidine-1-carboxamide;


N-Quinolin-7-yl-1-(5-trifluoromethylpyrid-2-yl)-piperidine-4-carboxamide;

N-Quinolin-7-yl-1-(6-trifluoromethylpyrid-2-yl)-piperidine-4-carboxamide;


N-Isoquinolin-5-yl-1-(5-trifluoromethylpyrid-2-yl)-piperidine-4-carboxamide; and

4-(4-Chlorophenyl)-N-(2-methylbenzothiazol-5-yl)cyclohexane-1-carboxamide.

2. (Original) A compound of formula (I), as claimed in claim 1, wherein P represents phenyl, quinolinyl, isoquinolinyl, benzoisoxazolyl or benzothiazolyl.
3. (Original) A compound of formula (I), as claimed in claim 2, wherein P represents phenyl.
4. (Original) A compound of formula (I), as claimed in claim 2, wherein P represents quinolinyl, isoquinolinyl, benzoisoxazolyl or benzothiazolyl.
5. (Original) A compound of formula (I), as claimed in claim 1, wherein P' represents phenyl.
6. (Original) A compound of formula (I), as claimed in claim 1, wherein P' represents pyridinyl or pyrimidinyl.
7. (Original) A compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof, as claimed in claim 1, substantially as hereinbefore described with reference to any one of the Examples.
8. (Original) A process for the preparation of a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof, as claimed in claim 1, which process comprises:
  - (a) reacting a compound of formula (II),



wherein, P, R<sup>1</sup> and n are as defined in relation to formula (I), with a compound of formula (III),



(III)

wherein, P', R<sup>2</sup>, m, n and X are as defined in relation to formula (I) and thereafter, as necessary, carrying out one or more of the following reactions:

- (i) converting one compound of formula (I) into another compound of formula (I);
- (ii) removing any protecting group;
- (iii) preparing a salt or a solvate of the compound so formed.

9. (Original) A pharmaceutical composition, which comprises a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof, as claimed in claim 1, and a pharmaceutically acceptable carrier or excipient therefor.

10. (Cancelled).

11. (Original) A method for the treatment or prophylaxis of disorders in which antagonism of the Vanilloid (VR1) receptor is beneficial, in particular the Disorders of the Invention, in mammals including humans, which method comprises administering to a mammal in need thereof a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof, as claimed in claim 1.

12. (Cancelled).